|
Exploitable Knowledge (description) |
Exploitable Products or Measure(s) |
Sector (s) of application |
Timetable for commercial use |
Patents or other IP protection |
Owner & Other Partner(s) involved |
Esté
(Partner 2) |
1.Multiparametric method for evaluating HIV envelope function |
Biological method |
1. Industrial
2. Academic |
Indeterminate |
Valorisation |
Partner 2 |
Dietrich (Partner 8) |
2. Multimeric therapeutic peptides |
Medicine |
Medical |
>2010 |
In preparation |
Partner 8 |
Mouscadet (Partner 19) |
3. A new assay for IN binding & activity using steady-state fluorescence anisotropy. |
Medicine |
Industrial |
- |
- |
Partner 11 and 19 |
Massa (Partner 17) |
4. Pre-clinical testing of antiviral compounds |
medicine |
1. medical
2. industrial |
2010 |
Planned |
TRIoH members, possibly others |
Engels (Partner 10) |
5. A new integrase inhibitor |
medicine |
1. medical
2. industrial |
2015 |
Planned (2006), |
Goethe Univ. (owner)
M.Witvrouw |
Vilarrasa (partner 4) |
6. first series of N-to-N linked nucleotides (as precursors of new RT inhibitors) |
RNase inhibitors |
pharmaceutical
industry |
2010 |
Planned in 2006-07 |
Partner 4 & Partner 2 |
Vilarrasa (partner 4) |
6. cont…first series of isonucleosides linked to diketo acids or diketo tetrazoles |
HIV integrase inhibitors |
pharmaceutical
industry |
2010 |
Planned in 2007 |
Partner 4 & Partner 1 |
Chimirri (Partner 7) |
7. Diketo Acid analogues as HIV-1 integrase inhibitors |
medicine |
1. medical
2. industrial |
|
Planned |
Partic. 7
Partic. 1a
Partic. 1b |
2005
|
Chimirri (Partner 7) |
8. Strand Transfer Integrase Inhibitors |
medicine |
1. medical
2. industrial |
|
Planned |
Partner 7
Partner 1a
Partner 1b |
Restle (Partner 20) |
9. Screening system (chip) for nucleic acid (5 - 7 bases) based drugs |
Drug screening method |
pharmaceutical industry |
2-3 years |
Patent |
Partner 20 |
Mouscadet
(partener 19) |
10. method for viral protein labelling in vitro and in cells |
Biological method |
1. academic |
Indeterminate |
Planned |
Part. 19 |
Mouscadet
(patner 19) |
11. New polyhydroxylated compounds inhibiting HIV-1 integrase |
Medicine |
1. industrial |
Indeterminate |
Planned |
External partner: Cotelle
Parter 19
Patner 1a
|
Keppler (Partner 14) |
12. Multi-transgenic rat model of HIV infection for efficient drug and pathogenesis testing |
Small animal model |
Medical |
2008 |
|
Gladstone Institutes, University of Heidelberg, Partner 14 |
Esté (Partner 2) |
13. Validation of new target for anti-HIV entry inhibitors in monocyte-derived cells |
New target for drug development |
pharmaceutical
industry |
|
foreseen |
Partner 2 |
Esté (Partner 2) |
14. Development of coreceptor antagonsit |
Medicine. New drug |
pharmaceutical
industry |
|
Protected |
Polyphor
Partner 2 |
Esté (Partner 2) |
15. Generation of stable cell lines expressing libraries of interfering RNA |
Biological method |
1. Industrial
2. Academic |
No commercial value foresee but available for use |
N.A. |
Partner 2 |
| 2006 |
|
|
|
|
|
|
| Vilarrasa (partner 4) |
16. Conjugates of 1,3-dioxopropil azoles and hydroxiquinoline derivatives with nucleosides
|
Dual target inhibitors |
pharmaceutical industry |
2010 |
2007 |
Partner 4, with participation of Partners 1a, 2, 1b
& 19 |
| Vilarrasa (partner 4) |
17. N-Hydroxy purines-2-carboxylates as alternatives to MK-0518
|
Integrase inhibitors |
pharmaceutical industry |
2010 |
2007 |
Partner 4, with partic. of Partners 1a & 1b (5) |
Veljkovic
(Partner 22) |
18. Peptide CCR5 inhibitors targeting ECL2 domain
|
Medicine |
Medical |
2010 |
Planned
(2007)
|
Partner 8 |
Mely
(P18) and Darlix (P3) |
19. screening system to search for anti-NC compounds
|
Pharmaceutical screening |
pharmaceutical |
- |
- |
Partner 1, 3 and 18 |
| Dietrich (Partner 8) |
20. HIV-1 entry mimotopes
|
Entry inhibitors or immunogens |
medical |
indeterminate |
- |
Partner 8 |
| Dietrich Partner 8) |
21. Multimeric entry inhibitors
|
medicine |
medical |
- |
- |
Partner 8 |
Dietrich/
von Laer (Partner 8) |
22. C46 resistant HIV-1
|
Basic science |
medical |
- |
- |
Partner 8 |
Chimirri
(partner 7) |
23. Pre-clinical testing of Strand Transfer Integrase Inhibitors
|
Medicine |
1. medical
2. industrial
3.academic |
- |
Planned |
Partner 7
Partner 1a
Partner 1b
Partner 14
Partner 25 |
| Chimirri (partner 7) |
24. New Integrase Inhibitors
|
chemistry
medicine |
1. medical
2. industrial
3.academic
|
- |
- |
Partner 7
Partner 1a
Partner 1b |
Chimirri
(partner 7 |
25. Rational design of Strand Transfer Integrase Inhibitors
|
computational and synthetic
approaches |
academic |
- |
- |
Partner 7
External partner: Cotelle |
| Chimirri (partner 7 |
26.Docking strudies of STINIs using Tn5 Transposase
|
computational and synthetic
approach |
academic |
- |
- |
Partner 7 |
Kaptein
(Partner 13) |
27. Engineering of HIV-1 Integrase core domain enabling NMR analysis of Integrase/inhibitor complexes
|
Lead compound optimization research tool |
Industrial and academic |
2007-2008 |
Planned in 2007 |
Partner 13 |
Restle /
Botta (20/17) |
28.New small molecule HIV-1 RT dimerization inhibitor
|
Medicine. New drug |
pharmaceutical
industry |
4 - 5 years |
N.A. |
Partner 20
Partner 17 |
Esté
(Partner 2) |
29. Novel anti-HIV agents targeting entry (CXCR4)
|
Anti-HIV compound |
1. Industrial |
Indeterminate |
Patent submitted
ES200602764 |
Partner 2 |
Esté
(Partner 2) |
30. Novel anti-HIV agent targeting macrophages
|
Anti-HIV compound |
1. Industrial |
Indeterminate |
- |
Partner 2 |
| Gottikh (Partner 11) |
31. Oligonucleotide inhibitors of HIV integrase and NC
|
Medicine. New drug |
1. Medical
2. Academic |
- |
- |
Partner 1, 3, 11, 18, 19 |
| Mouscadet (Partner 19)
|
32. New anti-integrase compounds
|
Medicine |
industrial |
indetermined |
Patent in preparation |
P19 and external partner (J. Polanski, Katowice, Poland) |
| Mouscadet (Partner 19) |
33. FISH metod to determine integration localization in cells
|
Method |
Axcademic |
No commercial value |
NA. |
Partner 19 |
Divita
(partner 9) |
34. Small peptide-based inhibitor of RT-dimerization
|
Medicine. New drug |
1. Medical
2. industry |
4-5 years |
Patent pending |
Partner 9 Partner 14External partner : P. Clayette
|
Divita
(partner 9) |
35. Small peptide-based inhibitor of Pol-poly-protein maturation
|
Medicine. New drug |
1. Medical
2. industry |
Indeterminate |
Planned |
Partner 9
Partner 1
Partner 19 |
Divita
(partner 9) |
36. Peptide-based nanoparticle for biomolecule delivery |
Medicine.
Basic Science
Diagnostic
|
1: Industrial
2: Academic |
On the market
“Deliver X” |
Patent Pending |
Partner 9 External Partner :Panomics Inc.
|
| Debyser – Witvrouw (partner 1) |
37. inhibitionof HIV integration by small proteins and peptides |
Pharmaceutical Therapy |
pharmaceutical |
7 years |
Patent application in progress |
Partner 1a, 1b |
| 2007 |
|
|
|
|
|
|
